Infections and Infectious Diseases | Drugs in Discovery

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas

Lead Product(s): mRNA vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Vaccine

Partner/Sponsor/Collaborator: Sanofi

Deal Size: $2,300.0 million Upfront Cash: $425.0 million

Deal Type: Expanded Collaboration June 23, 2020

Details:

The two companies will build upon their existing collaboration to pursue novel mRNA vaccines aimed at broadly addressing current and future infectious diseases.

Twist Bioscience

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Twist Bioscience Launches Two SARS-CoV-2 Antibody Panels to Expedite Research for COVID-19

Lead Product(s): Anti-SARS-CoV-2 S1 Antibody

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 28, 2020

Details:

The Twist anti-SARS-CoV-2 S1 Antibody Panel includes 32 human antibodies that bind with picomolar to nanomolar affinity to S1 spike protein on the SARS-CoV-2 virus.

VenatoRx Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Venatorx Pharmaceuticals Awarded up to $44.2 Million to Advance Novel Inhibitors of Penicillin Binding Proteins targeting WHO Critical Prior...

Lead Product(s): Non-beta-lactam antibiotic

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: NIAID

Deal Size: $44.2 million Upfront Cash: Undisclosed

Deal Type: Funding July 27, 2020

Details:

Funding aims to advance a novel series of Penicillin Binding Protein (PBP) Inhibitors targeting multi-drug resistant (MDR) Acinetobacter baumannii through Phase 1 clinical testing.

IRBM

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ITALY Italy

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

IRBM to Collaborate with MSD to Develop Peptides Against Coronavirus

Lead Product(s): Undisclosed

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Peptide

Partner/Sponsor/Collaborator: Merck & Co. Inc.

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration July 21, 2020

Details:

IRBM will leverage previous research into SARS to contribute to identifying and developing a potential treatment of SARS-CoV-2, as well as other future life-threatening coronavirus strains.

ZYUS Life Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

ZYUS Announces Positive Milestone in Plant-Based COVID-19 Vaccine Antigen Production

Lead Product(s): Plant-based COVID-19 antigen

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 15, 2020

Details:

Preliminary research results from ZYUS Life Sciences show that plant-based antigens are reactive to anti-COVID-19 antibodies and potentially offer immunity from COVID-19.

Hackensack Meridian CDI

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Hackensack Meridian Partners with Merck for Covid-19 Research

Lead Product(s): Undisclosed

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Merck & Co. Inc.

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership July 14, 2020

Details:

Hackensack Meridian CDI and Merck will work to discover drug candidates that can help treat Covid-19. Hackensack Meridian CDI will combine its expertise in academic drug discovery and viral pathogens analysis with Merck’s capabilities to discover and develop anti-infectives.

Dewpoint Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Dewpoint Therapeutics Collaborates with Merck to Evaluate Novel Approach for the Treatment of HIV

Lead Product(s): Undisclosed

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Merck & Co. Inc.

Deal Size: Undisclosed Upfront Cash: $305.0 million

Deal Type: Collaboration July 13, 2020

Details:

Merck will apply Dewpoint’s proprietary platform for condensate-based drug discovery for the development of a novel mechanism to treat HIV.

SciLifeLab

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Medivir and SciLifeLab Partner to Identify Covid-19 Drug Candidates

Lead Product(s): Undisclosed

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Medivir

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership July 06, 2020

Details:

The aim of the collaboration is to find potential inhibitors of the main protease of SARS CoV-2, an essential non-structural protein, Mpro, required for virus replication.

Immunomic Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Replicate Bioscience and Immunomic Therapeutics Form Collaboration

Lead Product(s): RBI-5000

Therapeutic Area: Infections and Infectious Diseases Product Name: RBI-5000

Highest Development Status: Discovery Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Replicate Bioscience

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement June 24, 2020

Details:

ITI and Replicate will develop candidates combining ITI’s UNITE technology with Replicate’s scalable self-replicating RNA (SynRGY technology) for COVID-19, HPV, and EBV.

Oblique Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Oblique Therapeutics AB has Identified a Potentially Important Epitope for Generation of SARS-CoV-2 antibodies

Lead Product(s): Undisclosed

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 11, 2020

Details:

Using the AbiprotTM antibody discovery platform, a team of researchers has identified a potentially important epitope in SARS-CoV-2 that may facilitate generation of neutralizing antibodies to treat Covid-19 patients.

Find

Find Novel Drugs for Infections and Infectious Diseases under Discovery

Discovery

Product Type

Companies

Sanofi

Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas

Twist Bioscience

Twist Bioscience Launches Two SARS-CoV-2 Antibody Panels to Expedite Research for COVID-19

VenatoRx Pharmaceuticals

Venatorx Pharmaceuticals Awarded up to $44.2 Million to Advance Novel Inhibitors of Penicillin Binding Proteins targeting WHO Critical Prior...

IRBM

IRBM to Collaborate with MSD to Develop Peptides Against Coronavirus

ZYUS Life Sciences

ZYUS Announces Positive Milestone in Plant-Based COVID-19 Vaccine Antigen Production

Hackensack Meridian CDI

Hackensack Meridian Partners with Merck for Covid-19 Research

Dewpoint Therapeutics

Dewpoint Therapeutics Collaborates with Merck to Evaluate Novel Approach for the Treatment of HIV

SciLifeLab

Medivir and SciLifeLab Partner to Identify Covid-19 Drug Candidates

Immunomic Therapeutics

Replicate Bioscience and Immunomic Therapeutics Form Collaboration

Oblique Therapeutics

Oblique Therapeutics AB has Identified a Potentially Important Epitope for Generation of SARS-CoV-2 antibodies